Functional analysis of single amino‐acid mutations in the thrombopoietin‐receptor Mpl underlying congenital amegakaryocytic thrombocytopenia

Congenital amegakaryocytic thrombocytopenia (CAMT) is a rare disorder that presents with severe thrombocytopenia and absence of megakaryocytes in the bone marrow. The disease may develop into bone marrow aplasia. Genetic defects in the gene encoding the thrombopoietin (Tpo) receptor, MPL, are the cause of this disease. In a previous study, we identified four missense mutations in CAMT patients, predicting Arg102Pro, Pro136His, Arg257Cys and Pro635Leu. To investigate whether these mutations result in defective Tpo‐binding and/or signalling, full‐length wildtype and mutant MPL were transduced into K562 cells. Expression levels and the ability to activate the mitogen‐activated protein kinase, Janus kinase‐signal transducer and activator of transcription and phosphoinositide‐3 kinase pathways upon Tpo‐binding were studied. The results predicted that MPL carrying the P136H or P635L mutation was not properly expressed, whereas the R102P and R257C mutations resulted in impaired signal transduction. Our results indicate that a severe clinical course may be expected when these mutations lead to absent Mpl expression or signalling in CAMT patients with missense mutations.

[1]  Lesley J. Murray,et al.  Thrombopoietin, flt3, and kit ligands together suppress apoptosis of human mobilized CD34+ cells and recruit primitive CD34+ Thy-1+ cells into rapid division. , 1999, Experimental hematology.

[2]  N. Saitou,et al.  Synonymous mutations in the human dopamine receptor D2 (DRD2) affect mRNA stability and synthesis of the receptor. , 2003, Human molecular genetics.

[3]  P. Noris,et al.  Congenital amegakaryocytic thrombocytopenia: clinical and biological consequences of five novel mutations , 2007, Haematologica.

[4]  J. Bussel,et al.  Three parameters, plasma thrombopoietin levels, plasma glycocalicin levels and megakaryocyte culture, distinguish between different causes of congenital thrombocytopenia , 2002, British journal of haematology.

[5]  A. Roberts,et al.  Hematopoietic stem cell deficiencies in mice lacking c-Mpl, the receptor for thrombopoietin. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[6]  Richard C Trembath,et al.  A synonymous SNP of the corneodesmosin gene leads to increased mRNA stability and demonstrates association with psoriasis across diverse ethnic groups. , 2004, Human molecular genetics.

[7]  K. Ihara,et al.  Congenital amegakaryocytic thrombocytopenia in three siblings: molecular analysis of atypical clinical presentation. , 2005, Experimental hematology.

[8]  M. Abecasis,et al.  Congenital amegakaryocytic thrombocytopenia—Report of a new c‐mpl gene missense mutation , 2007, American journal of hematology.

[9]  D. Kuter.  New thrombopoietic growth factors. , 2007, Blood.

[10]  Kindred A. Ritchie,et al.  Sustained ex vivo expansion of hematopoietic stem cells mediated by thrombopoietin. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[11]  S. Jacobsen,et al.  Ability of early acting cytokines to directly promote survival and suppress apoptosis of human primitive CD34+CD38- bone marrow cells with multilineage potential at the single-cell level: key role of thrombopoietin. , 1997, Blood.

[12]  W S Alexander,et al.  Deficiencies in progenitor cells of multiple hematopoietic lineages and defective megakaryocytopoiesis in mice lacking the thrombopoietic receptor c-Mpl. , 1996, Blood.

[13]  L. Bolund,et al.  Protein misfolding and degradation in genetic diseases , 1999, Human mutation.

[14]  K. Kaushansky.  Thrombopoietin: the primary regulator of platelet production. , 1995, Blood.

[15]  K. Kaushansky,et al.  The molecular mechanisms that control thrombopoiesis. , 2005, The Journal of clinical investigation.

[16]  M. Ballmaier,et al.  c-mpl mutations are the cause of congenital amegakaryocytic thrombocytopenia. , 2001, Blood.

[17]  M. Eguchi,et al.  Identification of mutations in the c-mpl gene in congenital amegakaryocytic thrombocytopenia. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[18]  L. Vitale,et al.  Compound heterozygosity for two different amino-acid substitution mutations in the thrombopoietin receptor (c-mpl gene) in congenital amegakaryocytic thrombocytopenia (CAMT) , 2000, Human Genetics.

[19]  Andrew G. Hall,et al.  Novel mutations in a child with congenital amegakaryocytic thrombocytopenia , 2006, British Journal of Haematology.

[20]  C. Folman,et al.  Mutations in the thrombopoietin receptor, Mpl, in children with congenital amegakaryocytic thrombocytopenia , 2000, British journal of haematology.

[21]  L. Rangell,et al.  Normal platelets and megakaryocytes are produced in vivo in the absence of thrombopoietin. , 1997, Blood.

[22]  M. Tsuchiya,et al.  A novel therapeutic approach for thrombocytopenia by minibody agonist of the thrombopoietin receptor. , 2005, Blood.

[23]  M. Souyri.  Mpl: from an acute myeloproliferative virus to the isolation of the long sought thrombopoietin. , 1998, Seminars in hematology.

[24]  W. Vainchenker,et al.  Oligodeoxynucleotides antisense to the proto-oncogene c-mpl specifically inhibit in vitro megakaryocytopoiesis. , 1993, Blood.

[25]  M. Ballmaier,et al.  Congenital amegakaryocytic thrombocytopenia: a retrospective clinical analysis of 20 patients , 2005, British journal of haematology.

[26]  M. Ballmaier,et al.  MPL mutations in 23 patients suffering from congenital amegakaryocytic thrombocytopenia: the type of mutation predicts the course of the disease , 2006, Human mutation.